
Brain Companies


Biopharmaceutical company given FDA clearance to study ketamine treatmentFebruary 26, 2022

New ETF allows investors to support Psychedelic Medicine CompaniesJune 18, 2021

MindMed declares Phase 1 trials for opioid addiction treatment successfulJuly 31, 2020
